Suchergebnisse - "Langer, Jakob"

PubPharm (101)

91

The association of body mass index with the risk of type 2 diabetes: a case–control study nested in an electronic health records system in the United States

enthalten in: Diabetology & metabolic syndrome | 2014

von Ganz, M. | Wintfeld, N. | Li, Q. | +3

92

Real-world cost-effectiveness : lower cost of treating patients to glycemic goal with liraglutide versus exenatide

enthalten in: Advances in therapy | 2014

von DeKoven, M. | Lee, W. | Bouchard, J. | +2

93

Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide

enthalten in: Advances in therapy | 2014

von DeKoven, M. | Lee, W. | Bouchard, J. | +2

94

Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide

enthalten in: Advances in therapy | 2014

von DeKoven, M. | Lee, W. | Bouchard, J. | +2

95

Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide

enthalten in: Advances in therapy | 2014

von DeKoven, M. | Lee, W. | Bouchard, J. | +2

96

Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg

enthalten in: Clinical therapeutics | 2013

von Malmenäs, M. | Bouchard, J. | Langer, J.

97

Retrospective Real-World Adherence in Patients With Type 2 Diabetes Initiating Once-Daily Liraglutide 1.8 mg or Twice-Daily Exenatide 10 μg

enthalten in: Clinical therapeutics | 2013

von Malmenäs, M. | Bouchard, J. | Langer, J.

98

Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States

enthalten in: Journal of managed care pharmacy : JMCP | 2013

von Langer, J. | Hunt, B. | Valentine, W.

99

Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes : a CORE Diabetes Model analysis

enthalten in: Journal of medical economics | 2012

von Lee, W. | Samyshkin, Y. | Langer, J. | +1

100

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents

enthalten in: Clinical therapeutics | 2011

von Valentine, W. | Palmer, A. | Lammert, M. | +2

[1]
« Vorheriger
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]